MétaCan
Menu
Back to cohort
Record W4416085364 · doi:10.1093/neuonc/noaf201.1178

IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

2025· article· en· W4416085364 on OpenAlexaff
Benjamin M. Ellingson, Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal, Mehdi Touat, Katherine B. Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust‐Katz, Liam Welsh, Warren Mason, François Ducray, Yoshie Umemura, Burt Nabors, Matthias Holdhoff, Andreas F. Hottinger, Yoshiki Arakawa, Juan Manuel Sepúlveda-Sánchez, Wolfgang Wick, Riccardo Soffietti, James Perry, Pierre Giglio, Macarena I. de la Fuente, Elizabeth A. Maher, Dan Zhao, Shuchi S. Pandya, Lori Steelman, Islam Hassan, Patrick Y. Wen, Timothy F. Cloughesy

Bibliographic record

VenueNeuro-Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsHealth Sciences CentreUniversity of TorontoSunnybrook Health Science CentreToronto General Hospital
Fundersnot available
KeywordsGliomaPlaceboIsocitrate dehydrogenaseConfidence intervalProportional hazards modelMultivariate analysisClinical trialAstrocytomaOligodendroglioma

Abstract

fetched live from OpenAlex

Abstract TGR shows emerging utility as a quantitative measure for assessing treatment efficacy in glioma. We evaluated three distinct TGR models using volumetric data from patients with mIDH1/2 diffuse glioma from the Phase 3 INDIGO trial (NCT04164901) to determine their predictive value for clinical outcomes. Data from the INDIGO trial comparing vorasidenib (n=168) with placebo (n=163) were analyzed. We assessed tumor growth patterns after treatment using: (1) a linear regression model (mL/6 months); (2) a bi-exponential model with growth parameter “g”; and (3) velocity of diametric expansion (VDE; mm/year). Individual TGRs were calculated during the first 6-month on-treatment period and correlated with progression-free survival (PFS) and time to next intervention (TTNI). Patients receiving vorasidenib demonstrated substantially lower on-treatment individual TGRs, compared with placebo, across all models (linear model: –0.037 vs 1.094 mL/6 months; bi-exponential: reduced “g” parameter, P<0.0001; VDE: –0.142 vs 2.280 mm/year). Quantile analysis revealed that patients with lower individual TGRs had notably better PFS and TTNI outcomes (P<0.0001). In Cox regression analysis, patient-specific TGR during first 6 months of treatment was strongly associated with both PFS (HR 1.046; 95% CI 1.026, 1.067; P<0.0001) and TTNI (HR 1.051; 95% CI 1.031, 1.072; P<0.0001). Holding other variables as constant, multivariate analysis identified treatment with vorasidenib versus placebo, an oligodendroglioma versus astrocytoma histological subtype, and, most notably, lower versus higher baseline tumor volume, as strong determinants for reduced individual TGRs. These findings demonstrate that individual TGRs are a robust quantitative measure for predicting outcomes in mIDH1/2 glioma. During the initial 6-month period, TGR was a strong predictor of long-term outcomes, supporting the utility of TGR as a potential surrogate endpoint in clinical trials and for treatment decision-making.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.014

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.355
Teacher spread0.315 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-OncologySame topicGlioma Diagnosis and TreatmentFrench-language works237,207